Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

Clinical trial NCT07472478 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07472478
Sponsor: Guangdong Provincial People's Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer (NSCLC)KRAS G12C Lung Cancer

Start date: 2026-03-15
Primary completion: 2027-12-31
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.